FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live AARTIDRUGS message board: Is AARTIDRUGS buy or sell? Should I buy AARTIDRUGS shares? Why are AARTIDRUGS shares falling? Should I invest in AARTIDRUGS stock?

forum

AARTIDRUGS Share Price Discussion

Aarti Drugs Ltd.
NSE: AARTIDRUGS | BSE: 524348 | ISIN: INE767A01016 | Sector: Pharmaceuticals and health care
N
Reputation: 6,184 • Aug 5 4:03 AM
Over 70 stocks in BSE500 hit 52-week high in July; time to chase momentum?
Experts say going ahead auto, pharma and chemicals sector look attractive. Analysts name 20 stocks that have a potential to outperform in August. These include Wockhardt, PI Industries and Rallis India
Moneycontrol
Like
Reply
NSE:AARTIDRUGS price when posted: 1,845
Recent posts in AARTIDRUGS

Type
Sell
Instrument
AARTIDRUGS
Entry Price
₹2,934.4
Price@Trade
₹2,934.4
Target Price
₹2,900
Stop Price
₹2,940
Valid Till
Sep 17, 2020 3:20 AM
Margin
₹117,376 approx for 40 Qty
Status
Validity Over
Exit Price
₹2,924.85
Net P&L
+₹382 (+0.33%)
Like
Reply (1)

Type
Sell
Instrument
AARTIDRUGS
Entry Price
₹2,984
Price@Trade
₹2,984
Target Price
₹2,960
Stop Price
₹2,999
Valid Till
Sep 16, 2020 3:20 AM
Margin
₹29,840 approx for 10 Qty
Status
Exited
Exit Price
₹2,984
Net P&L
₹0 (0%)
Like
Reply (1)
N
Reputation: 6,184 • Sep 15 5:38 AM
Fresh highs possible in ICICI Securities in next 4-6 months; here’s why
Companies having promoter integrity, high sector tailwinds, sales and profit growth sustenance, margins improvement are must to have which is what our 5GCPM framework focuses upon.
Moneycontrol
Like
Reply
N
Reputation: 6,184 • Sep 3 1:53 AM
Trade Spotlight: Adani Green, Zee Entertainment, CDSL & Aarti Drugs in focus
The action was seen in Adani Green rallied nearly 10% to hit a fresh 52-week high, CDSL rose more than 17% to hit a fresh 52-week high, Aart Drugs gained 5%, and ZEE Entertainment gained 8% on Wednesday.
Moneycontrol
Like
Reply (1)
N
Reputation: 6,184 • Aug 28 10:28 AM
These five API companies may benefit as drugmakers seek to reduce dependence on Chinese raw material
Both global and domestic drug companies are looking to diversify sourcing of Active Pharmaceutical Ingredients and Key Starting Materials from China. Indian companies, particularly pure-play API producers, are poised to tap this emerging opportunity.
Moneycontrol
Like
Reply